Massive study reveals COVID-19's toll on work and wages
NCT ID NCT07072793
First seen Jan 12, 2026 · Last updated May 24, 2026 · Updated 25 times
Summary
This study looked at over 131,000 high-risk adults in the US who had mild-to-moderate COVID-19 during the Omicron wave. Researchers compared those who took the antiviral Paxlovid with those who did not, measuring how many work days they missed and the costs of that lost work. The goal was to understand the economic impact of COVID-19 on people's ability to work.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 (CORONAVIRUS DISEASE 2019) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Pfizer New York
New York, New York, 10001, United States
Conditions
Explore the condition pages connected to this study.